SAB Biotherapeutics’ SAB-185 moves to Phase 3 trial for Covid-19 treatment
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
It paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses
Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Emergency Use Authorisation (EUA) is granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups
The initiative, with the support of MoHFW, will directly impact a population of more than 5.7 million that depend on the public health value chain across the 10 districts
The two startups will utilise the capital for business growth including strategic expansion, product development, R&D and technology investments
The recipient is a 57-year-old woman who was suffering from severe biventricular heart failure and had undergone cardiac surgery several years ago
The purchaser is a part of the portfolio companies of PE firm True North. The said transaction is not a related party transaction.
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
Subscribe To Our Newsletter & Stay Updated